
    
      This was a randomized, placebo-controlled, three-arm, parallel-group study designed to
      evaluate the efficacy, safety, and tolerability of dalfampridine extended release (ER)
      tablets on chronic walking deficits in subjects with post-ischemic stroke.
    
  